Domains and subdomains of Behçet syndrome endorsed by ≥ 70% of physician experts and/or patients as necessary to measure in clinical trials.
| Focus of Trial | Domains and Subdomains Endorsed* |
|---|---|
| All trials | Endorsed by both patients and physicians: activity, damage, death, function, patient’s global assessment, physician’s global assessment, quality of life, remission, work productivity |
| Endorsed by patients only: no. papulopustular lesions, pain of nodular lesions | |
| Mucocutaneous disease | Endorsed by both patients and physicians: duration of oral ulcers, duration of genital ulcers, duration of nodular lesions, new organ involvement, no. oral ulcers, no. genital ulcers, pain of genital ulcers, pain of oral ulcers |
| Endorsed by patients only: no. papulopustular lesions, pain of nodular lesions | |
| Ocular disease | Endorsed by both patients and physicians: blurry vision, cystoid macula edema, ocular attack, retinal vasculitis, visual acuity |
| Endorsed by patients only: duration of ocular attack, glucocorticoid tapering | |
| Vascular disease | Endorsed by both patients and physicians: disease-related damage, extended venous thrombus, hemoptysis, new aneurysm, new arterial thrombus, new venous thrombus, post-thrombotic syndrome |
| Endorsed by patients only: shortness of breath | |
| Neurologic disease | Endorsed by both patients and physicians: cognitive functioning, headache, progression on magnetic resonance imaging |
| Endorsed by patients only: disease-related damage, dizziness, neuropathic pain, neuropathy | |
| Gastrointestinal disease | Endorsed by both patients and physicians: abdominal pain, clinical remission, diarrhea, endoscopic remission |
| Endorsed by patients only: nausea, disease-related damage, weight loss | |
| Joint disease | Endorsed by both patients and physicians: duration of arthritis episodes, no. arthritis episodes, physical function, swollen joint count, tender joint count |
↵* Results based on responses by 56 patients and 74 physicians.